FDA Approves First Treatment for Peanut Allergy
The Food and Drug Administration (FDA) has approved Palforzia (Peanut [Arachis hypogaea] Allergen Powder-dnfp; Aimmune Therapeutics) for the treatment of peanut allergy.
Allergies
No Anaphylaxis Risk in Cardiac Catheterization With Beta-Blockers or ACE Inhibitors
Findings do not support the contention that patients undergoing cardiac catheterization should have their beta blockers or ACE inhibitors suspended.
Introducing Foods Early May Cut Development of Food Allergies
Early introduction of allergenic foods may prevent the development of food allergy in certain infants at high risk, although adherence to early introduction is low.
Proinflammatory Diet During Pregnancy Linked to Childhood Wheeze
A proinflammatory diet during pregnancy may be associated with early transient wheeze during childhood.
Risk for Hodgkin Lymphoma Increased With Allergic Disease, Eczema
The risk for Hodgkin lymphoma (HL) is increased in association with immunosuppression, allergic disease, and eczema.
Sesame-Specific IgE Levels May Help Diagnose Allergies
Sesame allergy affects 17 percent of children with IgE-mediated food allergy
Lower Birth Weight May Protect Against Allergies
Intrauterine growth restriction protects against allergic diseases.
Examining Potential Allergens in Adhesives Used for Diabetes Devices
Colophonium, a fast-acting adhesive and known sensitizing allergen, may cause dermatologic reactions in children using devices to manage diabetes.
FDA to Assess First Drug Meant to Prevent Peanut Allergy
Palforzia is a capsule containing a pharmaceutical-grade dose of the peanut protein.
EAACI Position Paper on the Role of Mobile Heath in Allergy Management
A task force created by the European Academy of Allergy and Clinical Immunology released recommendations and an action plan for the potential of mobile health in allergology.
Next post in Tech Talk
